AKBA
Akebia Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.07 / 10
Outperform
Analyst sentiment is strongly bullish (7.07/10) with two Strong Buy and one Buy recommendations. Fund‑flow score is 7.93, showing overall positive inflows; small and extra‑large investors are net buyers, while medium and large investors are net sellers. The outlook leans bullish.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
67%
Buy
33%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-06
InstitutionPiper Sandler
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for AKBA?
- AKBA holds a Bullish analyst rating, with 67% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.07/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
